olanzapine: Bipolar disorder

Olanzapine was the first of the atypical antipsychotics to be approved for the treatment of bipolar disorder.But weight gain is the main problem faced by patients.The American Psychiatric Association/American Diabetes Association Consensus Statement on Diabetes Care suggests monitoring patient weight at baseline, once a month for 3 months, and then quarterly. A fasting blood sugar should be taken at baseline, 3 months, and annually, and a fasting lipid profile should be taken at baseline, 3 months, and every 5 years afterwards